Triple-Negative Breast Cancer Clinical Trials

209 recruitingLast updated: June 17, 2026

There are 209 actively recruiting triple-negative breast cancer clinical trials across 43 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Triple-Negative Breast Cancer Trials at a Glance

209 actively recruiting trials for triple-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 102 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running triple-negative breast cancer studies include Fudan University, H. Lee Moffitt Cancer Center and Research Institute, and Memorial Sloan Kettering Cancer Center.

Browse triple-negative breast cancer trials by phase

Treatments under study

About Triple-Negative Breast Cancer Clinical Trials

Looking for clinical trials for Triple-Negative Breast Cancer? There are currently 159 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple-Negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple-Negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 209 trials

Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 2

Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.

TNBC - Triple-Negative Breast CancerBrain Metastasases
Fudan University58 enrolled1 locationNCT07638852
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled17 locationsNCT05768932
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled14 locationsNCT07211178
Recruiting
Phase 1

THE-0504 in Patients With Solid Tumors

Triple-Negative Breast CancerGastric Cancer (GC)Small Cell Lung Cancer ( SCLC )+2 more
Thena Biotech S.r.l.30 enrolled1 locationNCT07646106
Recruiting
Phase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Triple-Negative Breast CancerPancreatic CancerMelanoma+7 more
Memgen, Inc.40 enrolled2 locationsNCT05076760
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple-Negative Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor-Positive Breast Carcinoma+1 more
Laura Huppert, MD, BA36 enrolled1 locationNCT06224673
Recruiting
Phase 2

Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

Advanced Triple-Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences150 enrolled2 locationsNCT06771609
Recruiting
Phase 1

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Triple-Negative Breast CancerRenal Cell CarcinomaAlveolar Soft Part Sarcoma
Canadian Cancer Trials Group30 enrolled1 locationNCT07297667
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled299 locationsNCT06393374
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Early Phase 1

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Triple-Negative Breast Cancer
University of Alabama at Birmingham20 enrolled1 locationNCT04861077
Recruiting
Phase 2

Sacituzumab Govitecan In TNBC

Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Cancer+2 more
Massachusetts General Hospital260 enrolled5 locationsNCT04230109
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1Phase 2

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Triple-Negative Breast Cancer
NEC Bio B.V28 enrolled2 locationsNCT06631092
Recruiting
Phase 1Phase 2

Saci Nivo Rela for TNBC

Metastatic Triple-negative Breast Cancer
Yale University60 enrolled1 locationNCT06963905